2-Arachidonyl Glyceryl Ether, an Endogenous Agonist of The

Total Page:16

File Type:pdf, Size:1020Kb

2-Arachidonyl Glyceryl Ether, an Endogenous Agonist of The 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor Lumı´r Hanusˇ*, Saleh Abu-Lafi†, Ester Fride*‡, Aviva Breuer*, Zvi Vogel§, Deborah E. Shalev¶, Irina Kustanovich¶, and Raphael Mechoulam*ʈ *Department of Medicinal Chemistry and Natural Products, Hebrew University Medical Faculty, Jerusalem 91120, Israel; †Chemistry and Chemical Technology Department, Faculty of Science and Technology, P.O. Box 20002, Al-Quds University, Abu-Deis, West Bank, Palestinian Authority; ‡Department of Behavioral Sciences, College of Judea and Samaria, Ariel 88437, Israel; §Department of Neurobiology, The Weizmann Institute of Science, Rehovot 76100, Israel; and ¶Department of Biological Chemistry and The Wolfson Centre for Applied Structural Biology, Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem 91904, Israel Communicated by L. L. Iversen, University of Oxford, Oxford, United Kingdom, January 18, 2001 (received for review November 23, 2000) Two types of endogenous cannabinoid-receptor agonists have 2 kg of porcine brain, we obtained 0.5 mg of noladin ether, been identified thus far. They are the ethanolamides of polyun- approximately the amount of anandamide obtained from a saturated fatty acids—arachidonoyl ethanolamide (anandamide) is comparable extraction (1). the best known compound in the amide series—and 2-arachido- noyl glycerol, the only known endocannabinoid in the ester series. Preparation of Synaptosomal Membranes. Synaptosomal mem- We report now an example of a third, ether-type endocannabinoid, branes were prepared from the brains of Sabra male rats (250 g) 2-arachidonyl glyceryl ether (noladin ether), isolated from porcine after removal of the brainstem. The [3H]HU-243 probe, with a brain. The structure of noladin ether was determined by mass dissociation constant of 45 pM (11), was incubated with synap- spectrometry and nuclear magnetic resonance spectroscopy and tosomal membranes (3–4 ␮g) for 90 min at 30°C with the was confirmed by comparison with a synthetic sample. It binds to indicated concentrations of noladine ether or the vehicle alone ؎ ؍ the CB1 cannabinoid receptor (Ki 21.2 0.5 nM) and causes (fatty-acid-free BSA at a final concentration of 0.5 mg͞ml). sedation, hypothermia, intestinal immobility, and mild antinoci- Bound and free radioligand were separated by centrifugation ␮ ception in mice. It binds weakly to the CB2 receptor (Ki > 3 M). (see ref. 11 for full details of the assay). The data were normalized to 100% of specific binding, which was determined e have reported the isolation and identification of two with 50 nM unlabeled HU-243. Data points represent the Wtypes of endogenous cannabinoids that bind and activate average of triplicate determinations from three independent the known cannabinoid receptors CB1 and CB2. Arachidonoyl experiments. The Ki value was determined with a GraphPad (San ethanolamide (anandamide; ref. 1) and later two more polyun- Diego) PRISM 2.01 program that follows the Cheng-Prusoff equa- saturated fatty acid ethanol amides (2) were found in porcine tion (12). A sigmoid dose-response (variable slope) built-in brain. An ester, 2-arachidonoyl glycerol (2-AG) was isolated by equation in PRISMwas used to fit the curve shown in Fig. 2. us from canine gut (3) and by Sugiura et al. from brain (4). Anandamide and 2-AG have been the objects of numerous HPLC. The HPLC analysis was performed by using a Waters liquid investigations in various areas of biology and have been found to chromatograph (Millipore) equipped with a Photodiode Array affect processes in the nervous, cardiovascular, immune, and (model 996), 20- and 50-␮l loops, a Waters 600E multisolvent reproductive systems (5–8). They interact with many neurotrans- delivery system, and a Millennium 2010 chromatography man- mitters and affect hormone levels (9–10). This ubiquity of effects ager for the analysis of data. A reversed-phase Waters Symmetry led us to look for additional endocannabinoids. C18 column (5 ␮m, 250 ϫ 4.6 mm i.d.) was used. Reversed-phase We report now that we have isolated from porcine brain a third solvents were HPLC grade. Acetonitrile was purchased from endocannabinoid, 2-arachidonyl glyceryl ether, which we have J. T. Baker. Water was doubly distilled and filtered by using a named noladin ether (Fig. 1). 0.2-␮m cellulose mixed ester membrane (Schleicher & Schuell). Before injection into the HPLC, the sample was filtered by Materials and Methods loading concentrated methanol extract onto a 0.2-␮m Gelman Isolation of Noladin Ether. Porcine brain (100 g, approximately a nylon syringe filter. single brain) was added to a mixture of chloroform (200 ml) and The analyses were run under isocratic conditions at ambient methanol (200 ml) and mixed in a blender for 2 min. Water (100 temperature. The optimized mobile phase used for the isolation ml) was added, and the mixing process was continued for another of the active noladin ether was acetonitrile͞water [70:30 (vol͞ minute. The mixture was filtered. Two layers were formed. The vol)]. The flow rate was 1.5 ml͞min, and the monitoring wave- water-methanol layer was separated and evaporated under re- length was 210 nm. Under these conditions, noladin ether elutes duced pressure. The residue obtained was extracted with meth- at 22.88 min. Of 4.5 mg of column fraction, 0.5 mg of pure anol. The above isolation was repeated numerous times (from a noladin ether was obtained. total of 2.4 kg porcine brain). The extract obtained was chro- Synthetic standard (noladin ether) was injected by using the matographed on a gravity column (i.d. 2.5 cm, height 28 cm, 82 g same working conditions. Similar elution time was noticed for ICN Silica TSC, 60 A) with hexane͞acetone initially in a ratio of both compounds. After comparing the UV͞Vis spectrum of the 10:1 (vol͞vol) (400 ml), then 9:1 (100 ml), and finally 4:1 (100 synthetic compound with extracted noladin ether, excellent ml). The fractions eluted were monitored for binding to the CB1 matching was obtained (Fig. 3). Moreover, when a synthetic receptor from rat brain synaptosomes (prepared as described below; ref. 11) on the basis of displacement of the potent labeled agonist [3H]HU-243 purchased from Tocris (Bristol, U.K.). The Abbreviations: 2-AG, 2-arachidonoyl glycerol; 2D, two-dimensional. ʈ material eluted in fractions 45–54 (10-ml each) was found to bind To whom reprint requests should be addressed at: Hebrew University, Department of Medicinal Chemistry and Natural Products, Faculty of Medicine, Ein Kerem Campus, to the receptor. These fractions were combined and purified Jerusalem 91120, Israel. E-mail: [email protected]. further by HPLC (see below). A polar-active compound devel- ͞ The publication costs of this article were defrayed in part by page charge payment. This oped on a TLC plate (silica gel 60 F254, Merck) in a hexane article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. ϭ acetone (4:1) solvent system gave a single spot (Rf 0.13). From §1734 solely to indicate this fact. 3662–3665 ͉ PNAS ͉ March 27, 2001 ͉ vol. 98 ͉ no. 7 www.pnas.org͞cgi͞doi͞10.1073͞pnas.061029898 Downloaded by guest on October 2, 2021 Fig. 1. Synthesis of noladin ether: step a, LiAlH4͞ether, 25°C; step b, CH3SO2Cl͞pyridine, 25°C; step c, benzylideneglycerol-KOH͞benzene, 25°C; step d, HCl͞CH3OH, 25°C. Percentages indicate yields of reactions. sample was spiked with natural noladin ether and injected into 0.25 mm ϫ 0.25 ␮m. Experimental conditions were: inlet, 250°C; the HPLC, one single peak was eluted at 22.88 min. Waters detector, 280°C; splitless injection͞purge time, 1.0 min; initial MILLENNIUM software purity calculations confirmed the exis- temperature, 70°C; initial time, 3.0 min; rate, 30°C͞min; final tence of only one component under this peak. temperature, 280°C. The MS spectrum is presented in Fig. 4. MS. A Hewlett Packard G 1800B GCD system that has a HP-5971 NMR Spectroscopy. NMR spectra were acquired on a Bruker GC with electron ionization detector was used. The software used (Billerica, MA) Advanced DMX 600-MHz spectrometer. Proton was GCD PLUS CHEMSTATION. The column used was HP-5 chemical shifts at 295.0 K were referenced to chloroform at 7.26 (crosslinked 5% PH ME siloxane) with a film thickness of 28 m ϫ and 77.0 ppm for proton and carbon signals, respectively. One- and two-dimensional (2D) homo- and heteronuclear data were collected at natural abundance by using 2D-correlated spectros- copy, 2D double-quantum filtered correlated spectroscopy, 2D total-correlation spectroscopy, and 2D heteronuclear multiple- quantum correlation experiments. All NMR data were processed by using XWINNMR 2.6 software (Bruker) running on Silicon Graphics (Mountain View, CA) INDY workstations. Zero-filling and suitable apodization func- tions were applied to enhance the spectral resolution. The spectra were analyzed by using Aurelia 2.7.5 software (Bruker). The one-dimensional proton spectra and the 2D-correlated spectroscopy and total-correlation spectroscopy spectra of nat- ural and synthetic noladin were compared and found to be identical under the acquisition conditions. The chemically iden- tical alkene methine protons 6, 7, 9, 10, 12, 13, 15, and 16 are overlapped, as are the methylene protons 8, 11, and 14 that have double bonds at both sides. The alkane protons 2 and 3 are CHEMISTRY Fig. 2. Competitive inhibition of [3H]HU-243 binding by natural noladin Fig. 3. Overlay of HPLC chromatograms of natural and synthetic noladin ether. For details see Materials and Methods. ether. For details see Materials and Methods. Hanusˇ et al. PNAS ͉ March 27, 2001 ͉ vol. 98 ͉ no. 7 ͉ 3663 Downloaded by guest on October 2, 2021 Fig. 4. Electron impact͞mass spectrum of di(trimethylsilyl) derivative of natural noladin ether.
Recommended publications
  • Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System
    International Journal of Molecular Sciences Review Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System Shenglong Zou and Ujendra Kumar * Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-604-827-3660; Fax: +1-604-822-3035 Received: 9 February 2018; Accepted: 11 March 2018; Published: 13 March 2018 Abstract: The biological effects of cannabinoids, the major constituents of the ancient medicinal plant Cannabis sativa (marijuana) are mediated by two members of the G-protein coupled receptor family, cannabinoid receptors 1 (CB1R) and 2. The CB1R is the prominent subtype in the central nervous system (CNS) and has drawn great attention as a potential therapeutic avenue in several pathological conditions, including neuropsychological disorders and neurodegenerative diseases. Furthermore, cannabinoids also modulate signal transduction pathways and exert profound effects at peripheral sites. Although cannabinoids have therapeutic potential, their psychoactive effects have largely limited their use in clinical practice. In this review, we briefly summarized our knowledge of cannabinoids and the endocannabinoid system, focusing on the CB1R and the CNS, with emphasis on recent breakthroughs in the field. We aim to define several potential roles of cannabinoid receptors in the modulation of signaling pathways and in association with several pathophysiological conditions. We believe that the therapeutic significance of cannabinoids is masked by the adverse effects and here alternative strategies are discussed to take therapeutic advantage of cannabinoids. Keywords: cannabinoid; endocannabinoid; receptor; signaling; central nervous system 1. Introduction The plant Cannabis sativa, better known as marijuana, has long been used for medical purpose throughout human history.
    [Show full text]
  • N-Acyl-Dopamines: Novel Synthetic CB1 Cannabinoid-Receptor Ligands
    Biochem. J. (2000) 351, 817–824 (Printed in Great Britain) 817 N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo Tiziana BISOGNO*, Dominique MELCK*, Mikhail Yu. BOBROV†, Natalia M. GRETSKAYA†, Vladimir V. BEZUGLOV†, Luciano DE PETROCELLIS‡ and Vincenzo DI MARZO*1 *Istituto per la Chimica di Molecole di Interesse Biologico, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy, †Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, R. A. S., 16/10 Miklukho-Maklaya Str., 117871 Moscow GSP7, Russia, and ‡Istituto di Cibernetica, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy We reported previously that synthetic amides of polyunsaturated selectivity for the anandamide transporter over FAAH. AA-DA fatty acids with bioactive amines can result in substances that (0.1–10 µM) did not displace D1 and D2 dopamine-receptor interact with proteins of the endogenous cannabinoid system high-affinity ligands from rat brain membranes, thus suggesting (ECS). Here we synthesized a series of N-acyl-dopamines that this compound has little affinity for these receptors. AA-DA (NADAs) and studied their effects on the anandamide membrane was more potent and efficacious than anandamide as a CB" transporter, the anandamide amidohydrolase (fatty acid amide agonist, as assessed by measuring the stimulatory effect on intra- hydrolase, FAAH) and the two cannabinoid receptor subtypes, cellular Ca#+ mobilization in undifferentiated N18TG2 neuro- CB" and CB#. NADAs competitively inhibited FAAH from blastoma cells. This effect of AA-DA was counteracted by the l µ N18TG2 cells (IC&! 19–100 M), as well as the binding of the CB" antagonist SR141716A.
    [Show full text]
  • N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation Via Nonhematopoietic TRPV1
    N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1 This information is current as Samira K. Lawton, Fengyun Xu, Alphonso Tran, Erika of October 1, 2021. Wong, Arun Prakash, Mark Schumacher, Judith Hellman and Kevin Wilhelmsen J Immunol 2017; 199:1465-1475; Prepublished online 12 July 2017; doi: 10.4049/jimmunol.1602151 http://www.jimmunol.org/content/199/4/1465 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2017/07/12/jimmunol.160215 Material 1.DCSupplemental http://www.jimmunol.org/ References This article cites 69 articles, 11 of which you can access for free at: http://www.jimmunol.org/content/199/4/1465.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on October 1, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Author Choice Freely available online through The Journal of Immunology Author Choice option Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1 Samira K.
    [Show full text]
  • The Cannabinoid Receptor Agonist WIN 55,212-2 Attenuates the Effects Induced by Quinolinic Acid in the Rat Striatum
    Neuropharmacology 51 (2006) 1004e1012 www.elsevier.com/locate/neuropharm The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum A. Pintor a, M.T. Tebano a, A. Martire a, R. Grieco a, M. Galluzzo a, M.L. Scattoni b,A.Pe`zzola a, R. Coccurello c, F. Felici a, V. Cuomo d, D. Piomelli e, G. Calamandrei b, P. Popoli a,* a Department of Drug Research and Evaluation, Central Nervous System Pharmacology Division, Istituto Superiore di Sanita`, Viale Regina Elena, 299, 00161 Rome, Italy b Department of Cell Biology and Neuroscience, Istituto Superiore di Sanita`, Viale Regina Elena, 299, 00161 Rome, Italy c Institute of Neuroscience, EBRI Foundation, Rome, Italy d Department of Pharmacology and General Physiology, University ‘‘La Sapienza’’, Rome, Italy e Department of Pharmacology and Center for Drug Discovery, University of California, Irvine, CA, USA Received 7 April 2006; received in revised form 15 May 2006; accepted 16 June 2006 Abstract The ability of CB1 receptors to regulate the release of glutamate in the striatum, together with the finding that, in experimental models of Huntington disease (HD), both endocannabinoid levels and CB1 receptor densities are reduced, has prompted the investigation on the neuropro- tective role of the cannabinoids in HD. Quinolinic acid (QA) is an excitotoxin that, when injected in the rat striatum reproduces many features of HD and that acts by stimulating glutamate outflow. The aim of the present study was to test the ability of the cannabinoid receptor agonist WIN 55,212-2 to prevent the effects induced by QA in the rat striatum.
    [Show full text]
  • Safe Access to Medical Cannabis in New Mexico Schools a Guide Prepared for Tisha Brick by Jason Barker with Safe Access New Mexico
    Safe Access To Medical Cannabis in New Mexico Schools A guide prepared for Tisha Brick by Jason Barker with Safe Access New Mexico Safe Access New Mexico ~ A Chapter of Americans For Safe Access UNITE-NETWORK-GROW-INFORM-KNOW-EDUCATE-ACTIVISM-VOTE-HEALTH-WELLNESS (All Rights Reserved 04/20/2018) 1 Program Participants Should Be Able To Use Medical Cannabis At Schools We've come a long way since cannabis was first decriminalized in Oregon in 1973 and then in New Mexico; medical cannabis history started in 1978, after public hearings the legislature enacted H.B. 329, the nation’s first law recognizing the medical value of cannabis…the first law. And it has now been over a decade since the passage of the Lynn and Erin Compassionate Use Act. Safe Access for those patients who will benefit most from medical cannabis treatments; still need to overcome political, social and legal barriers with advocacy by creating policies that improve access to medical cannabis for patients - and that means at school too. Schools already allow children to use all kinds of psychotropic medications—from Ritalin to opioid painkillers—when prescribed by a physician. 2 States That Allow Safe Access To Medical Cannabis In Schools New Jersey - 2015 * Maine - 2015 * Colorado - 2016 (1st Jack’s Law) & 2018 Washington - 2016 Pennsylvania - 2017 Illinois - 2018 (* States Program is Modelled after New Mexico’s Medical Cannabis Program) 3 New Jersey in November 2015 became the first state to do so. Governor Christie signed a bill directing all school districts in New Jersey to adopt rules that permit children with developmental disabilities to consume cannabis oil or another edible cannabis product.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
    International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions.
    [Show full text]
  • The Cannabinoid WIN 55,212-2 Prevents Neuroendocrine Differentiation of Lncap Prostate Cancer Cells
    OPEN Prostate Cancer and Prostatic Diseases (2016) 19, 248–257 www.nature.com/pcan ORIGINAL ARTICLE The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells C Morell1, A Bort1, D Vara2, A Ramos-Torres1, N Rodríguez-Henche1 and I Díaz-Laviada1 BACKGROUND: Neuroendocrine (NE) differentiation represents a common feature of prostate cancer and is associated with accelerated disease progression and poor clinical outcome. Nowadays, there is no treatment for this aggressive form of prostate cancer. The aim of this study was to determine the influence of the cannabinoid WIN 55,212-2 (WIN, a non-selective cannabinoid CB1 and CB2 receptor agonist) on the NE differentiation of prostate cancer cells. METHODS: NE differentiation of prostate cancer LNCaP cells was induced by serum deprivation or by incubation with interleukin-6, for 6 days. Levels of NE markers and signaling proteins were determined by western blotting. Levels of cannabinoid receptors were determined by quantitative PCR. The involvement of signaling cascades was investigated by pharmacological inhibition and small interfering RNA. RESULTS: The differentiated LNCaP cells exhibited neurite outgrowth, and increased the expression of the typical NE markers neuron-specific enolase and βIII tubulin (βIII Tub). Treatment with 3 μM WIN inhibited NK differentiation of LNCaP cells. The cannabinoid WIN downregulated the PI3K/Akt/mTOR signaling pathway, resulting in NE differentiation inhibition. In addition, an activation of AMP-activated protein kinase (AMPK) was observed in WIN-treated cells, which correlated with a decrease in the NE markers expression. Our results also show that during NE differentiation the expression of cannabinoid receptors CB1 and CB2 dramatically decreases.
    [Show full text]
  • Cannabinoids: Novel Molecules with Significant Clinical Utility
    CANNABINOIDS: NOVEL MOLECULES WITH SIGNIFICANT CLINICAL UTILITY NOEL ROBERT WILLIAMS MD FACOG DIRECTOR OPTIMAL HEALTH ASSOCIATES OKLAHOMA CITY, OKLAHOMA How Did We Get Here? • In November 2012 Tikun Olam, an Israeli medical cannabis facility, announced a new strain of the plant which has only CBD as an active ingredient, and virtually no THC, providing some of the medicinal benefits of cannabis without euphoria. The Researchers said the cannabis plant, enriched with CBD, “can be used for treating diseases like rheumatoid arthritis, colitis, liver inflammation, heart disease and diabetes.” Cannabis CBD like in this article is legally derived from the hemp plant. • CBD is the major non-psychoactive component of Cannabis Sativa (Hemp). Hemp plants are selectively developed and grown to contain high amounts of CBD and very low amounts of the psychoactive component THC found in marijuana. A few CBD oil manufacturers further purify their products to contain high amounts of CBD and no THC. 2014 Farm Bill Terminology • Active Ingredient • Zero THC • Cannabidiol • Isolate • PCR – Phytocannabinoid-Rich • Hemp Oil Extract • “Recommendation” vs. “Prescribed” • Full Spectrum Endocannabinoids (AEA) Phytocannabinoids Full Spectrum & Active Ingredient • CBD – Cannabidiol • A major phytocannabinoid, accounting for as much as 85% of the plant’s extract • CBC – Cannabichromene • Anti-inflammatory & anti-fungal effects have been seen • CBG – Cannabigerol • The parent molecule from which many other cannabinoids are made • CBDV – Cannabidivarin • A homolog of CBD that has been reported to have powerful anti-convulsive effects • CBN – Cannabinol • Sleep & Appetite regulation • Terpenes • Wide spectrum of non-psychoactive molecules that are know to act on neural receptors and neurotransmitters, enhance norepinephrine activity, and potentially increases dopamine activity.
    [Show full text]
  • The Determination of CBD and General Cannabinoid Content In
    No. SSI-HPLC-018 High Performance Liquid Chromatography The Determination of CBD and General Cannabinoid Content in Hemp Oils Using HPLC with UV Detection No. HPLC-018 ■ Introduction Medical marijuana generally possesses high levels of CBD oil is derived as concentrate from CO2 or the therapeutic cannabidiol, CBD, and lower levels butane extraction of hemp, sometimes followed by (generally less than 0.3%) of the psychotropic steam distillation or ethanol distillation for tetrahydrocannabinol, d9-THC. Pain mitigation and purification. The Farm Bill of 2014 distinguishes reduced severity of nausea and seizures are just a hemp from marijuana, yet interpreting the law is few of the therapeutic benefits reported by medical difficult in that “CBD oil” may be classified as cannabis patients. Little has been done to better marijuana. understand the chemistry of benefits from CBD. To complicate matters, there is evidence that a The FDA has issued warning letters to firms that combination of CBD, a host of other minor market unapproved new drugs allegedly contain cannabinoids and a complex array of terpenoids may CBD. As part of these actions, the FDA has be the most beneficial – called the “entourage determined the cannabinoid content of some hemp effect.” CBD-rich oil has become increasingly products and many were found to contain levels of popular and is administered via sublingual drops, gel CBD that are very different from the label claim. It is capsules or as a topical ointment. important to note that such products are not approved by the FDA for the diagnosis, cure, The main source of CBD-rich oil is industrial hemp.
    [Show full text]
  • Mechoulam on Cannabidiol by Fred Gardner a Lipid
    O’Shaughnessy’s • Winter/Spring 2008 —31— An Overview at the IACM meeting in Cologne Mechoulam on Cannabidiol By Fred Gardner a lipid. Sophisticated analytical tech- wonder, then, that CBD plays a role in The emerging significance of can- niques and brilliant, dedicated lab work- many clinical conditions. nabis components other than THC was ers (“They should not be married so they Conditions treatable by CBD again a prominent theme when the can work 24 hours a day, seven days a Mechoulam described an experiment International Association of Cannabis week”) enabled Mechoulam to isolate a led by Paul Consroe and colleagues in as Medicine met in Cologne in early cannabinoid produced by the body itself Brazil in which CBD was tested as a October, 2007. The IACM was founded —arachidonoyl-ethanolamide or AEA, treatment for intractable epilepsy. Pa- in 1997 by Franjo Grotenhermen, MD which his colleague William Devane tients stayed on the anticonvulsants they (as the German ACM); it is a smaller dubbed “anandamide,” incorporating the had been on (which hadn’t eliminated organization than the ICRS and its focus Sanskrit word for “bliss.” their seizures) and added 200mg/day of is more clinical, less pharmacological. CBD or a placebo. Of the seven patients “There is almost no physi- getting CBD over the course of several Mechoulam thought his ological system that has been months, only one showed no improve- study of cannabis would be “a ment; three became seizure-free; one looked into in which endocan- experienced only one or two seizures, minor project, it will be finished nabinoids don’t play a certain Mechoulam recalled; and two experi- photo by Alon Weinstock Alon by photo off in six months.” part.” enced reduced severity and occurrence of seizures.
    [Show full text]
  • Cannabis – the Israeli Perspective
    J Basic Clin Physiol Pharmacol 2016; 27(3): 181–187 Review Raphael Mechoulam* Cannabis – the Israeli perspective DOI 10.1515/jbcpp-2015-0091 customs. Burning cannabis and inhaling the smoke made Received July 28, 2015; accepted July 29, 2015; previously published them ‘howl in joy’ [1]. online September 30, 2015 Surprisingly, in ancient Judea, cannabis was appar- ently unknown. Or, if it was used as a medicine, it was Abstract: Short overviews are presented on the histori- ignored in the Bible, as it was part of the prevalent Assyr- cal uses of cannabis in the Middle East and on the more ian customs and culture, which after the empire of Assyria recent scientific and medical research on phytocannabi- disintegrated (around 6th century B.C.), the Judean noids and the endocannabinoid system, with emphasis leaders tried to suppress. However, it may be mentioned on research contributions from Israel. These are followed in the Bible as panag – an unidentified product exported by examples of research projects and clinical trials with to Tyre [2]. cannabinoids and by a short report on the regulation of The Greeks and the Romans, who were in the Middle medical marijuana in Israel, which at present is adminis- East for many centuries, were not aware of the psycho- tered to over 22,000 patients. activity of cannabis, but they used it as a medicinal Keywords: anandamide; 2-arachidonoyl glycerol (2-AG); agent, mostly for some types of pain and inflammations. cannabidiol (CBD); tetrahydrocannabinol (THC). However, Galen was aware that it produces ‘senseless talk’ [1]. In medieval Arab society, for over a millennium, In memory of Professor Itai Bab, a close friend and dedicated researcher.
    [Show full text]